Personalis Secures Expanded Medicare Coverage for NeXT Personal Test in Breast Cancer Monitoring
PSNL has more than doubled off its 52-week low of $3.84.
Summary
Personalis announced expanded Medicare coverage for its NeXT Personal test, now including monitoring treatment response for specific breast cancer types, which is crucial for its commercial strategy and revenue potential.
Key Events · Product Development and Regulatory · PSNL
-
Expanded Medicare Coverage
The Centers for Medicare & Medicaid Services (CMS) expanded Medicare coverage for Personalis's ultrasensitive NeXT Personal test. This new coverage includes monitoring treatment response to neoadjuvant therapy in patients with Stage II-III Triple-Negative Breast Cancer or HER2-positive breast cancer.
-
Boosts Market Access
This expansion significantly broadens the addressable market for the NeXT Personal test, enhancing its commercial viability and potential for revenue growth in a critical oncology segment.
Analysis · PSNL · Industrial Applications And Services
This expanded Medicare coverage for the NeXT Personal test to include monitoring treatment response in Stage II-III Triple-Negative and HER2-positive breast cancer patients is a significant positive development. It broadens the market for Personalis's key diagnostic product, directly impacting potential revenue growth and commercial adoption. This news is particularly important given the company's recent financial challenges and its focus on clinical growth, following previous Medicare coverage expansions.
At the time of this filing, PSNL was trading at $7.98 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $832.5M. The 52-week trading range was $3.84 to $11.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.